Cardiovascular risk and the COVID-19 pandemic: a population-based and case‒control studies

Table 4 The value of cardiovascular risk and the frequency of CV risk classes of the studied populations

Variable	Group I N = 691	Group II N = 816	P	Group III N = 126	Control group IV N = 126	P
SCORE 2 & 2OP, %	5.7 ± 5.2	6.2 ± 5.6	0.203	6.7 ± 4.9	7.2 ± 5.3	0.553
FS-Lipids, %	9.4 ± 9.0	9.4 ± 9.0	0.918	11.0 ± 8.6	13.9 ± 9.8	0.017
FS-BMI, %	11.9 ± 10.3	11.6 ± 10.3	0.678	14.0 ± 9.4	17.6 ± 10.6	0.009
LIFE-CVD 10-year risk, %	3.7 ± 4.1	3.7 ± 3.6	0.880	4.0 ± 3.1	5.6 ± 5.7	0.008
LIFE-CVD lifetime risk, %	22.9 ± 10.2	22.1 ± 9.7	0.199	24.8 ± 9.8	26.5 ± 11.3	0.228
CVD-free life-expectancy	87.8 ± 7.5	87.7 ± 7.2	0.879	88.7 ± 5.3	87.7 ± 5.7	0.180
Low to moderate CV risk class^*	439 (63.5)	482 (59.1)	0.189	44 (34.9)	47 (37.3)	0.916
High CV risk class^*	166 (24.0)	214 (26.2)		51 (40.5)	50 (39.7)
Very-high CV risk class^*	86 (12.4)	120 (14.7)		31 (24.6)	29 (23.0)

The data is shown as n (%), mean (SD). BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; FRS, Framingham Risk Score; LIFE-CVD, LIFEtime-perspective model for individualizing CardioVascular Disease prevention strategies in apparently healthy people; SCORE 2OP, Systematic Coronary Risk Estimation 2 and Systematic Coronary Risk Estimation 2-Older Persons risk; SD, standard deviation.
^*The study population was divided into CV risk classes in line with 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol, 2021

ISSN: 1478-7954